Year All20242023202220212020201920182017 Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024 Mar 26, 2024 Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights Mar 12, 2024 Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference Feb 26, 2024 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 06, 2024 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Dec 05, 2023 Inozyme Pharma to Participate in Upcoming Investor Conferences Nov 09, 2023 Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights Nov 07, 2023 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 03, 2023 Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023 Oct 26, 2023 Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions Oct 10, 2023
Year All20242023202220212020201920182017 Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024 Mar 26, 2024 Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights Mar 12, 2024 Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference Feb 26, 2024 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 06, 2024 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Dec 05, 2023 Inozyme Pharma to Participate in Upcoming Investor Conferences Nov 09, 2023 Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights Nov 07, 2023 Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 03, 2023 Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023 Oct 26, 2023 Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions Oct 10, 2023
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024 Mar 26, 2024
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights Mar 12, 2024
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights Nov 07, 2023
Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023 Oct 26, 2023
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions Oct 10, 2023